Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.

NCT04711161 is registered in ClinicalTrials.gov with Green3Bio, Inc. as lead sponsor.

NCT NCT04711161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04711161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
Lead sponsor
Green3Bio, Inc.
Phase
Phase 1
Overall status
Suspended
Start date
December 21, 2020
Completion date
March 31, 2025
Enrollment
73 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian tumors